French Court Invalidates Insulet Patent Claims, Dismissing Over €3M Claim Against Medtrum

WISECODE Take

Many companies assume that obtaining a preliminary injunction secures market victory, but it is essentially a leveraged operation carrying liability risks. On September 4, 2026, the Judicial Court of Paris invalidated claims of Insulet's European Patent EP 2 438 957 for lack of inventive step, rejecting over €3 million in damages claims against Medtrum and ordering Insulet to pay €50,000 as an advance payment for damages caused by the injunction. For exporting companies, initiating patent invalidation is crucial when facing litigation; businesses not operating in Europe remain unaffected. Chidian provides patent portfolio checkups to clarify stability and infringement risks prior to international expansion. Businesses facing overseas IP litigation should consider two steps: first, file invalidation actions against the asserting patent concurrently when sued; second, document all channel and sales losses incurred during injunctions for future cross-claims. Initiating patent litigation without confirming patent validity ultimately converts the temporary market restriction into self-inflicted financial liability.